{"id":"bdb-001-injection","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reaction"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the target and modulating its activity, leading to a therapeutic effect.","oneSentence":"BDB-001 injection is a monoclonal antibody targeting a specific molecular target.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:46.610Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07168161","phase":"PHASE3","title":"BDB-001 Phase III Trial in ANCA-Associated Vasculitis","status":"RECRUITING","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2025-11-10","conditions":"ANCA Associated Vasculitis (AAV)","enrollment":300},{"nctId":"NCT05197842","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2022-02-22","conditions":"ANCA-associated Vasculitis","enrollment":93},{"nctId":"NCT04449588","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS","status":"TERMINATED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2020-07-23","conditions":"COVID-19 Pneumonia","enrollment":369},{"nctId":"NCT05075304","phase":"PHASE1","title":"A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients","status":"TERMINATED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2020-02-21","conditions":"COVID-19","enrollment":18},{"nctId":"NCT05103423","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2021-06-24","conditions":"Hidradenitis Suppurativa","enrollment":50},{"nctId":"NCT05093855","phase":"PHASE2","title":"Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2021-08-18","conditions":"Hidradenitis Suppurativa","enrollment":41},{"nctId":"NCT05361005","phase":"PHASE1","title":"Tolerability and Safety of BDB-001 Injection in Healthy Subjects","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2020-03-12","conditions":"Healthy","enrollment":33},{"nctId":"NCT05360927","phase":"PHASE1","title":"Safety and Tolerability of BDB-001 Injection in Healthy Subjects","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2019-09-25","conditions":"Healthy","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BDB-001 injection","genericName":"BDB-001 injection","companyName":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","companyId":"staidson-beijing-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BDB-001 injection is a monoclonal antibody targeting a specific molecular target. Used for Metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}